Intra-cellular therapies submits supplemental new drug application (snda) to fda for caplyta® (lumateperone) for the treatment of major depressive disorder as adjunctive therapy

Bedminster, n.j., dec. 03, 2024 (globe newswire) -- intra-cellular therapies, inc. (nasdaq: itci), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (cns) disorders, announced that it has recently submitted a supplemental new drug application (snda) to the u.s. food and drug administration (fda) for caplyta (lumateperone) for the treatment of major depressive disorder (mdd) in adults, as adjunctive therapy to antidepressants.
ITCI Ratings Summary
ITCI Quant Ranking